Emergency Contraceptive Pills Market: North America Leads with Promising Growth Opportunities and Outlook to 2031
January 31, 2024 10:31 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Emergency Contraceptive Pills Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Femtech Market Predicted to Surge, Fuelled by Technological Advances and Women-Centric Health Solutions
January 15, 2024 12:23 ET
|
Research and Markets
Dublin, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The "Femtech Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research...
Progestin Options Set to Dominate Contraceptive Pills Market: Insights from 2023 to 2030
September 25, 2023 07:28 ET
|
Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Global Contraceptive Pills Market by Hormone Type (Combination Pills, Progestin Pills), Category (Branded, Generic) - Cumulative Impact of COVID-19,...
Global Femtech Market Report (2022 to 2028) - Players Include Google, HeraMED, iSono Health and Chiaro Technology
July 11, 2022 05:18 ET
|
Research and Markets
Dublin, July 11, 2022 (GLOBE NEWSWIRE) -- The "Global Femtech Market Size, Share & Industry Trends Analysis Report By Product Type, By Mobile Apps Type, By Regional Outlook and Forecast, 2022 -...
Agile Therapeutics Reports Third Quarter 2017 Financial Results
November 06, 2017 16:20 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017 PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics to Host First Analyst Day on October 10, 2017
October 02, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
September 07, 2017 07:50 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE...
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
June 27, 2017 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...
Agile Therapeutics Reports First Quarter 2017 Financial Results
May 08, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three months ended March 31, 2017, and...
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
April 11, 2017 07:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...